The goal of this study is to create a topical gel for drug delivery with antifungal effects. The preparation containing Fluconazole and Clindamycin was selected for preparation. The system delivers the drug at the specified time required by the patient to achieve maximum efficacy and improve drug efficacy with minimal side effects. To combat both topical and systemic fungal infections, doctors use fluconazole, an imidazole derivative. Because of its many negative side effects, fluconazole should not be used orally. Clindamycin is most commonly used to treat anaerobic infections, which are caused by anaerobic bacteria that are amenable to clindamycin's treatment and have very little effect. The purpose of the current investigation was to develop and assess a variety of topical gel formulations including fixed dose combination of fluconazole with Clindamycin mainly accelerate the anti-fungal effect by acting on fungus as well as reduce development of bacteria’s associated with that. Carbopol 940, Hydroxypropyl methylcellulose E4M, Methyl cellulose, Pectin, and Pluronic P407 were used to manufacture the gel at varying concentrations. The simultaneous determination of medicine in dose form was developed using the simultaneous equation approach. DSC and FT-IR analyses confirmed that the drug and excipients were compatible with one another. A modified Franz diffusion cell was used to evaluate drug penetration across a cellulose membrane and drug release in vitro in a phosphate buffer at pH 5.5. To test the efficacy of the developed formulations against Candida albicans, a model fungus, we employed Nizoral® cream as a gold standard. The greatest values came from F3 (91.3% of drug released after 2 hr) in in vitro drug release and permeation experiments. Even in terms of antifungal action, F3 is superior than the others. Also, for the chosen formula, the stability analysis found no noticeable change between the two time points.